Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Neumora Therapeutics, Inc.

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces Leadership Transition
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Participate in Upcoming Conferences in May
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Tickers NMRA
Neumora Therapeutics Announces Pricing of Initial Public Offering
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
From Neumora Therapeutics, Inc.
Via Business Wire
Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer
From Neumora Therapeutics, Inc.
Via Business Wire
Neumora Therapeutics Announces $112 Million Series B Financing
From Neumora Therapeutics, Inc.
Via Business Wire
Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University
From Neumora Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.